Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.883,97
0,75%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Curis Inc (CRIS) Curis Inc (CRIS) Notizie

Curis Inc

CRIS
14,47
-0,05 (-0,34%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
05/4/202413:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04/4/202413:30PRNUSCuris to Present at Upcoming Healthcare Conferences in April
12/2/202422:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202422:36EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/2/202422:27EDGAR2Form S-3 - Registration statement under Securities Act of..
08/2/202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/2/202414:01EDGAR2Form 8-K - Current report
08/2/202414:00PRNUSCuris Provides Fourth Quarter 2023 Business Update
01/2/202414:00PRNUSCuris to Release Fourth Quarter 2023 Financial Results and..
11/1/202414:13EDGAR2Form 8-K - Current report
05/1/202414:00PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
21/12/202322:00EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
12/12/202314:00PRNUSCuris Announces Initial Combination Study Data from its..
11/12/202314:00PRNUSCuris Presented Clinical Data from the TakeAim Leukemia..
06/12/202314:00PRNUSCuris Announces Three Presentations at ASH
05/12/202314:00PRNUSCuris Enters into Agreement for Emavusertib / Pembrolizumab..
02/11/202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202313:01EDGAR2Form 8-K - Current report
02/11/202313:00PRNUSCuris Provides Third Quarter 2023 Business Update
26/10/202314:30PRNUSCuris to Release Third Quarter 2023 Financial Results and..
06/10/202314:56PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
28/9/202322:05EDGAR2Form 8-K/A - Current report: [Amend]
28/9/202314:54EDGAR2Form 8-K - Current report
12/9/202314:00PRNUSCuris Announces Date for the 2nd Symposium on IRAK4 in..
06/9/202314:13PRNUSCuris to Present at Upcoming Healthcare Conferences in..
18/8/202322:02EDGAR2Form DEF 14A - Other definitive proxy statements
04/8/202322:09EDGAR2Form PRE 14A - Other preliminary proxy statements
03/8/202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:02EDGAR2Form 8-K - Current report
03/8/202322:01PRNUSCuris Provides Second Quarter 2023 Business Update
28/7/202300:25PRNUSCuris to Release Second Quarter 2023 Financial Results and..
06/7/202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/7/202315:28EDGAR2Form 8-K - Current report
06/7/202314:04EDGAR2Form 8-K - Current report
06/7/202314:01PRNUSFDA Removes Partial Clinical Hold on TakeAim Leukemia Study..
06/7/202314:00PRNUSCuris Announces $15.1 Million Registered Direct Offering
05/5/202313:30PRNUSCuris Reports Inducement Grants Under NASDAQ Listing Rule..
04/5/202322:01PRNUSCuris Provides First Quarter 2023 Business Update
Apertura: 14,44 Min: 14,25 Max: 14,6899
Chiusura: 14,52

La tua Cronologia

NASDAQ
CRIS
Curis
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network